Article Link: FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas 13 April 2...
FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Article Link: FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CR...
FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Article Link: FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult an...
FDA Approves Sevenfact (coagulation factor VIIa [recombinant]-jncw) for Adults and Adolescents with Hemophilia A or B and Inhibitors
Article Link: FDA Approves Sevenfact (coagulation factor VIIa [recombinant]-jncw) for Adults and Adolescents with Hemophilia A or B and Inhibitors...
Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
Article Link: Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer 30 March 2020 — AstraZeneca’s Imfi...
Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Article Link: Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psori...
FDA Approves Triferic AVNU (ferric pyrophosphate citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
Article Link: FDA Approves Triferic AVNU (ferric pyrophosphate citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance o...
FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
Article Link: FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis PRINCETON, N.J.–(BUSINESS WIRE)–Brist...
FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
Article Link: FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infectio...
FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype
Article Link: FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype �...
